MiguelAEscobarMD

PubMed

• Hemostatic efficacy of four factor prothrombin complex concentrate in intracerebral hemorrhage patients receiving warfarin vs. factor Xa inhibitors.
  Gregory Pon, Brittany Pelsue, Sujan Teegala Reddy, Kaushik Parsha, Xu Zhang, Brian Gulbis, Andrew Barreto, Sean I Savitz, Miguel Escobar, Teresa A Allison> ;Thrombosis Research. 2023 Sep 1
• Impact of switching prophylaxis treatment from factor VIII to emicizumab in hemophilia A patients without inhibitors.
  Miguel Escobar, Neha Agrawal, Sagnik Chatterjee, Swastik Bhattacharya, Jorge Caicedo, Michael Bullano, Bob G Schultz> ;Journal of Medical Economics. 2023 Mar 29
• 8 citations
  Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research priorities to transform the care of people wit...
  Duc Q Tran, Craig C Benson, Judith A Boice, Meera Chitlur, Amy L Dunn, Miguel A Escobar, Kalpna Gupta, Jill M Johnsen, James Jorgenson, Scott D Martin, Suzanne Martin,...> ;Expert Review of Hematology. 2023 Mar 1
• Targeting an elevated FVIII level using personalized rurioctocog alfa pegol prophylaxis in specific patient populations with hemophilia A:subanalysis of the randomized...
  Carmen Escuriola-Ettingshausen, Robert Klamroth, Oleksandra Stasyshyn, Srilatha Tangada, Werner Engl, Ivan Honauer, Hye-Youn Lee, Pratima Chowdary, Jerzy Windyga, Esco...> ;Therapeutic Advances in Hematology. 2023 Jan 1
• 3 citations
  World federation of hemophilia international hemophilia training fellowship program: 50 years of enhancing global care.
  Miguel A Escobar, Marlène Beijlevelt, Aleah Loney, Johnny Mahlangu, Lochana Nanayakkara, Daniela Neme, Gianluigi Pasta, Pierre Toulon, Huyen Tran> ;Haemophilia. 2022 Sep 1
• Hemophilia A: Strategies for Improving Long-Term Holistic Management, Adherence, and Quality of Life.
  Miguel A Escobar, Cindy Leissinger, Guy Young> ;Journal of the Advanced Practitioner in Oncology. 2022 May 1
• 12 citations
  Recombinant von Willebrand factor prophylaxis in patients with severe von Willebrand disease: phase 3 study results.
  Frank W G Leebeek, Flora Peyvandi, Miguel Escobar, Andreas Tiede, Giancarlo Castaman, Michael Wang, Tung Wynn, Jovanna Baptista, Yi Wang, Jingmei Zhang, Björn Mellgård...> ;Blood. 2022 Jul 14
• 14 citations
  Postoperative bleeding complications in patients with hemophilia undergoing major orthopedic surgery: A prospective multicenter observational study.
  Brendan Kleiboer, Marcus A Layer, Lorraine A Cafuir, Adam Cuker, Miguel Escobar, M Elaine Eyster, Eric Kraut, Andrew D Leavitt, Steven R Lentz, Doris Quon, Margaret V ...> ;Journal of Thrombosis and Haemostasis. 2022 Apr 1
• 20 citations
  Integrated Hemophilia Patient Care via a National Network of Care Centers in the United States: A Model for Rare Coagulation Disorders.
  Leonard A. Valentino, Judith Baker, Regina Butler, Miguel A. Escobar, Neil Frick, Susan Karp, Kollet Koulianos, Susan Lattimore, Diane J. Nugent, Joseph N Pugliese, Mi...> ;Journal of Blood Medicine. 2021 Oct 21
• 6 citations
  The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitors
  Miguel A. Escobar, Giancarlo Castaman, Santiago Bonanad Boix, Michael U. Callaghan, Philippe de Moerloose, Jonathan M. Ducore, Cédric Hermans, Janna M. Journeycake, Ci...> ;Haemophilia. 2021 Oct 11
• 5 citations
  PERSEPT 3: A phase 3 clinical trial to evaluate the haemostatic efficacy of eptacog beta (recombinant human FVIIa) in perioperative care in subjects with haemophilia A...
  Miguel A. Escobar, James V. Luck, Yevhenii Averianov, Jonathan M. Ducore, Maria Fernanda Lopez Fernandez, Adam Giermasz, Daniel P. Hart, Janna M. Journeycake, Craig M....> ;Haemophilia. 2021 Oct 6
• 9 citations
  F5-Atlanta: A novel mutation in F5 associated with enhanced East Texas splicing and FV-short production
  Karen L. Zimowski, Teodolinda Petrillo, Michelle D. Ho, Julie Wechsler, Jordan E Shields, Gabriela Denning, Navdeep Jhita, Angel A Rivera, Miguel A. Escobar, Christine...> ;Journal of Thrombosis and Haemostasis. 2021 Mar 27
• 2 citations
  Immune tolerance induction with antihaemophilia factor (human) in poor prognosis patients with haemophilia A.
  Miguel A. Escobar, Linda G. Shaffer, Mark Holguin, Timothy L. McCavit, Novinyo S. Amega, Sandeep K. Rajan> ;Haemophilia. 2021 Feb 3
• What proceduralists need to know about emicizumab for patients with hemophilia A.
  Evan G. Pivalizza, Miguel A. Escobar> ;Proceedings. 2021 Mar 4
• 80 citations
  BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression
  Barbara A. Konkle, Christopher E. Walsh, Miguel A. Escobar, Neil C. Josephson, Guy Young, Annette von Drygalski, Scott W.J. McPhee, R. Jude Samulski, Ivan Bilic, Mauru...> ;Blood. 2021 Feb 11
• 11 citations
  Real-world data demonstrate improved bleed control and extended dosing intervals for patients with haemophilia B after switching to recombinant factor IX Fc fusion pro...
  Amy D. Shapiro, Ateefa Chaudhury, Michael Wang, Miguel A. Escobar, Elisa Tsao, Christopher Barnowski, Jing Feng, Nisha Jain, Doris Quon> ;Haemophilia. 2020 Oct 4
• 34 citations
  Evaluation of the Use of Low-Dose 4-Factor Prothrombin Complex Concentrate in the Reversal of Direct Oral Anticoagulants in Bleeding Patients.
  Teresa A. Allison, Pei Jen Lin, Jennifer A. Gass, Kenneth Chong, Samuel J Prater, Miguel A Escobar, Heather Hartman> ;Journal of Intensive Care Medicine. 2020 Sep 1
• 6 citations
  Optimal trough levels in haemophilia B: Raising expectations
  Christopher E. Walsh, Michiel Coppens, Miguel A. Escobar, Michael Wang> ;Haemophilia. 2020 Aug 25
• Comparison of polyspecific versus IgG specific ELISA in predominately cardiac patients with suspected heparin induced thrombocytopenia
  Sophie Samuel, Mary F. McGuire, Jennifer Cortes, Miguel A. Escobar, Phillip Weeks, Andy Nguyen> ;Journal of Thrombosis and Thrombolysis. 2020 Jan 1
• 4 citations
  Quantitative HLA‐class‐II/factor VIII (FVIII) peptidomic variation in dendritic cells correlates with the immunogenic potential of therapeutic FVIII proteins in hemoph...
  Vincent P. Diego, Bernadette W. Luu, Marco Hofmann, Long V. Dinh, Marcio Almeida, Jerry S. Powell, Raja Rajalingam, Juan M. Peralta, Satish Kumar, Joanne E. Curran, Zu...> ;Journal of Thrombosis and Haemostasis. 2020 Jan 1
• Efficacy of EHL N9-GP for on-demand treatment of bleeding episodes in hemophilia B: analysis of pivotal trial data.
  Miguel A. Escobar, Christopher E. Walsh, David L. Cooper, Guy Young> ;Journal of Blood Medicine. 2019 Jul 25
• 22 citations
  Once‐weekly prophylaxis with glycoPEGylated recombinant factor VIII (N8‐GP) in severe haemophilia A: Safety and efficacy results from pathfinder 2 (randomized phase II...
  Nicola Curry, Canan Albayrak, Miguel A. Escobar, Pål Andre Holme, Susan Kearney, Robert Klamroth, Mudi Misgav, Claude Negrier, Allison P. Wheeler, Elena Santagostino, ...> ;Haemophilia. 2019 Feb 28
• 13 citations
  Switching patients in the age of long-acting recombinant products?
  Miguel A. Escobar, Elena Santagostino, Maria Elisa Mancuso, Michiel Coppens, Vinod Balasa, Jason A. Taylor, Alfonso Iorio, Claude Negrier> ;Expert Review of Hematology. 2019 Jan 14
• 21 citations
  Clinical utility of viscoelastic testing (TEG and ROTEM analyzers) in the management of old and new therapies for hemophilia.
  Sarah Ramiz, Guy Young, Miguel A. Escobar, Meera Chitlur> ;American Journal of Hematology. 2018 Dec 7
• 27 citations
  Identification and Characterization of Novel Mutations Implicated in Congenital Fibrinogen Disorders
  Natalie Smith, Larissa Bornikova, Leila Noetzli, Hugo A. Guglielmone, Salvador Minoldo, Donald S. Backos, Linda J. Jacobson, Courtney D. Thornburg, Miguel A. Escobar, ...> ;Research and Practice in Thrombosis and Haemostasis. 2018 Oct 1
• Join now to see all

Journal Articles

• Switching patients in the age of long-acting recombinant products?  
  Escobar, M. Santagostino E, Mancuso ME, Coppens M, et al., Expert Review of Hematology, 1/1/2019
• cross-sectional analysis of cardiovascular disease in the hemophilia population  
  Sood SL, Cheng D, Ragni M, Kessler CM, Quon D, Shapiro AD, Key NS, Manco-Johnson MJ, Cuker A, Kempton C, Wang T, Eyster ME, Kuriakose P, von Drygalski A, Gill JC, Whee..., Blood Advances, 1/1/2018
• Identification and characterization of novel mutations implicated in congenital fibrinogen disorders  
  Smith N, Bornokova L, Noetzli L, Guglielmone H, Minoldo S, Backos D, Jacobson L, Thornburn C, Escobar M, et al., Research and Practice in Thrombosis and Haemostasis, 1/1/2018
• Low-factor consumption for major surgery in haemophilia B with long-acting recombinant glycoPEGylated factor IX  
  Escobar MA, Tehranchi R, Karim A, Caliskan U, Chowdary P, et al., Haemophilia, 1/1/2017
• Major and minor classifications for surgery in people with hemophilia: A literature review  
  Solimeno LP, Escobar MA, Krassova S, Seremetis S, Clin Appl Thromb Hemost., 1/1/2017
• Safety and efficacy of recombinant activated coagulation factor VII in congenital hemophilia with inhibitors in the home treatment setting: A review of clinical studie...  
  Young G, Escobar MA, Pipe SW, Cooper DL, Am J Hematol, 1/1/2017
• Unnecessary use of inferior vena cava filters: a teachable moment  
  Goswamy RV, Maiti A, Escobar MA, JAMA Intern Med, 1/1/2017
• Experience of a new high-purity factor X concentrate in subjects with hereditary factor X deficiency undergoing surgery  
  Escobar MA, G. Auerswald, S. Austin, J. N. Huang, M. Norton and C. M. Millar, Haemophilia, 1/1/2016
• Antifactor Xa levels vs activated partial thromboplastin time for monitoring unfractionated heparin A pilot study  
  Samuel S, Allison TA, Sharaf S, Yau G, Ranjbar G, Mckaig N, Nguyen A, Escobar M, and Choi HA, Journal of Clinical Pharmacy and Therapeutics, 1/1/2016
• Efficacy and safety of rVIII-SingleChain: results of a phase I/III multicenter clinical trial in severe hemophilia A  
  Mahlangu J, Kuliczkowski K, Abdul Karim F, Stasyshyn O, Kosinova MV, Lepatan LM, Skotnicki A, Boggio LN, Klamroth R, Oldenburg J, Hellman A, Santagostino E, Baker RI, ..., Blood, 1/1/2016
• Providing hemostatic and blood conservation options for Jehovah�s witness patients in a large medical system  
  Bai, Y., Castillo, BS., Tchakarov, A., Escobar, MA., Cotton, BA., et al., Annals of Clinical & Laboratory Science, 1/1/2016
• Recombinant activated factor VII in the treatment of bleeds and for the prevention of surgery-related bleeding in congenital hemophilia with inhibitors  
  Santagostino E, Escobar M, Ozelo M, Solimeno L, et al., Blood Reviews, 1/1/2015
• Characteristics of hemophilia patients with factor VIII inhibitors detected by prospective screening  
  Miller CH, Rice AS, Boylan B, Payne AB, Kelly FM, Escobar MA, et al., Am J Hematol, 1/1/2015
• Optimising musculoskeletal care for patients with haemophilia  
  Carcao M, Hilliard P, Escobar M, Solimeno L, Mahlangu J, Santagostino E, Eur J Haematol, 1/1/2015
• Hemophilia A and hemophilia B: focus on arthropathy and variables affecting bleeding severity and prophylaxis  
  Escobar, M.A., Sallah, S., Journal of Thrombosis and Haemostasis, 1/1/2013
• Advances in the treatment of inherited coagulation disorders  
  Escobar, M.A., Haemophilia, 1/1/2013
• Utilization Patterns and Associated Costs of Factor Assistance Programs among Persons with Hemophilia: A Single Institution Review  
  Khleif, A., Rodriguez, N., Brown, D., Escobar, M.A., Haemophilia, 1/1/2012
• Best Practices for the Multidisciplinary Management of Patients with Hemophilia with Inhibitors Undergoing Surgery in the United States  
  Escobar, M.A, Maahs, J, Hellman, E, Donkin, J, Forsyth, A, Hroma, N, et al., Haemophilia, 1/1/2012
• Bleeding in the Patient with a Malignancy  
  Escobar, M.A., Cancer, 1/1/2012
• Total joint replacement in advanced haemophilic arthropathy: A review of outcome, complications, impact of HIV and Inhibitors  
  Rodriguez-Merchan, EC, Rodriguez, NI, Escobar, M.A., Journal of Clinical Rheumatology & Musculoskeletal Medicine, 1/1/2012
• Multiple Co-morbid Conditions Among Middle-aged and Elderly Hemophilia Patients: Prevalence Estimates and Implications for Future Care  
  Khleif, A., Rodriguez, N., Brown, D., and Escobar, M.A., Journal of Aging Research, 1/1/2011
• Health Economics in Haemophilia: A review from the clinician�s perspective  
  Escobar, M.A., Haemophilia, 1/1/2010
• Neutralization of genetically diverse HIV-1 strains by IgA antibodies to the gp120�CD4-binding site from long-term survivors of HIV infection  
  Planque, S., Salas, M., Mitsuda, Y., Sienczyk, M., Escobar, M.A., et.al., AIDS, 1/1/2010
• Progressive multifocal leukoencephalopathy in a patient without apparent immunosuppression  
  Vaklavas, C., Otelo-Rafiq, EP., Lovy, J., Escobar, M.A. and Tsimberidou, AM., Virology Journal, 1/1/2010
• In non-severe hemophilia A the risk of inhibitor after intensive factor treatment is greater in older patients: a case-control study  
  Kempton CL, Soucie FM, Miller CH, Hooper C, Escobar M.A., Cohen AJ, Key NS, Thompson AR, and Abshire TC, J Thromb Haemost, 1/1/2010
• Join now to see all

Books/Book Chapters

• Williams Hematology 
  Chapter: Hemophilia A and Hemophilia B 
  Escobar, MA and Reding M.Editors: Beutler E., et al..McGraw HillEdition 10,2021
• Management of Bleeding Patients 
  Chapter: Known bleeding disorders for surgery. 
  Escobar, M.A., Nguyen T.T., Montanez N.Editors: J. Teruya.SpringerEdition 2,2021
• Consultative Hemostasis and Thrombosis 
  Chapter: Less common congenital disorders of hemostasis. 
  Escobar, MA.Editors: CS Kitchens, et al..W.B. Saunders CompanyEdition 4,2019
• The Core Topics of Aortic Disease 
  Chapter: Strategy for heparin-induced thrombocytopenia and anticoagulation replacement therapy. 
  Hall AC and Escobar MAEditors: S Zhou and A Estrera.Liaoning Science and Technology Publishing House2018
• Textbook of Haemophilia 
  Chapter: Products used to treat haemophilia: Dosing. 
  Escobar M.A.Editors: Lee, K Hoots and E Berntop.Blackwell Publishing2014
• Encyclopedia of Human Biology 
  Chapter: Hemophilia 
  Escobar, M.A., Nguyen T.T.Willey-Blackwell2014
• Hemophilia and Hemostasis: A Case-Based Approach to Management 
  Ma, DA., Roberts, HR., Escobar, MAWilley-BlackwellEdition Seco,2012
• Williams Hematology 
  Chapter: Hemophilia A and Hemophilia B 
  Roberts, H.R., Key, N., Escobar, M.A.Editors: Beutler E., et al..McGraw HillEdition Eigh,2010
• Textbook of Haemophilia 
  Chapter: Products used to treat haemophilia: Dosing 
  Escobar M.A.Editors: C Lee, K Hoots and E Berntop.Blackwell Publishing2010
• Evidence- based Hematology 
  Chapter: Diagnosis and management of acquired bleeding disorders: Vitamin K antagonists. 
  Escobar, M.A.Editors: Crowther, M., Ginsberg, J., et al..Blackwell Publishing2008
• PocketMedicine/Internal Medicine 
  Chapter: Thrombophilia. 
  Escobar, M.A., Roberts, H.R. and Ma, A.Editors: B.F. Scharschmidt.2007
• Lange Q&A. USMLE Step 3 Fourth Edition 
  Brisco, A.D.; Escobar, MA (Contributor)McGraw-HillEdition 4th,2007
• Lange Q&A. USMLE Step 3 Fifth Edition 
  Brisco, A.D.; Escobar, MA (Contributor)McGraw-HillEdition 5th,2007
• Hemostasis and Thrombosis: basic principles and clinical practice 
  Chapter: Inherited disorders of prothrombin conversion. 
  Roberts, H.R., Escobar, M.A.Editors: Colman RW, Hirsh J, Marder VJ et al..Lippincott Williams & WilkinsEdition Fift,2006
• Hematology: Basic Principles and Practice. 
  Chapter: Other clotting factor deficiencies. 
  Roberts, HR, Escobar, M.A.Editors: Hoffman R., et al..Churchill LivingstoneEdition Four,2005
• Textbook of Haemophilia 
  Escobar M.A.Editors: C Lee, K Hoots and E Berntop.Blackwell Publishing2005
• Pocket Medicine/Internal Medicine 
  Chapter: Thrombophilia. 
  Escobar, M.A., Roberts, H.R. and Ma, A.Editors: B.F. Scharschmidt.2002
• Thrombosis and Hemorrhage. 
  Chapter: Other coagulation factor deficiencies. 
  Roberts, H.R. and Escobar, M.A.Editors: J Loscalzo and AI Schafer.Williams & Wilkins CompanyEdition Thir,2002
• Hemofilia 
  Chapter: Concentrados purificados en el tratamiento de la hemofilia. 
  Page 389 - 396Escobar, M.A.Editors: CM Murillo, et al..Editorial Prado, S.A.2001
• Join now to see all

Abstracts/Posters

• The Dendritic Cell HLA-Class-II/Therapeutic Factor VIII (FVIII) Peptidome Is Influenced in Unanticipated Ways By the B-Domain of FVIII and the FVIII Chaperon Protein, ...
  Miguel A. Escobar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• On the Role of F8 Sequence Mismatch and Class-II Human Leukocyte Antigen Binding in the Development of Neutralizing Antibodies (Inhibitors) Directed Against Therapeuti...
  Miguel A. Escobar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Safety and efficacy of N9-GP, a recombinant glycoPEGylated factor IX with extended half-life, in US vs global patients with hemophilia B: results from the paradigm� cl...
  Young G, Lentz SR, Kearney S, Escobar M, Seremetis S, Cooper DL, Walsh C, THSNA, 1/1/2018
• Chronic Kidney Disease in the U.S. Hemophilia Population: A Cohort Study.
  Sood SL, Cheng D, Shapiro AD, Kessler CM,Key NS, Quon DV, Eyster E, Manco-Johnson MJ, Kempton CL,Cuker A, Ragni MV, Gill JC, Kuriakose P, Drygalski A, Kouides PA, Esco..., THSNA, 1/1/2018
• Comparison of rFIX utilization and bleed rates in US hemophilia B patients on rIX-FP and their prior rFIX drug.
  Escobar M, Leissinger C, Yan S, Maro G, Krishnarajah G, Res Prac Thromb Haemost, 1/1/2018
• Pharmacoeconomic analysis of direct thrombin inhibitors using polyspecific ELISA antibodies in suspected heparin induced thrombocytopenia.
  Samuel S , McGuire MF, Cortes J, Weeks P, Brown RS, Nguyen A, Escobar M, Thrombosis & Hemostasis Societies of North America (THSNA), 1/1/2018
• Pharmaco-economic analysis of direct thrombin inhibitors using IgG Specific ELISA antibodies in suspected heparin induced thrombocytopenia.
  Samuel S, McGuire MF, Cortes J, Weeks P, Brown RS, Nguyen A, Escobar M, THSNA, 1/1/2018
• Coagulation Factor Use Evaluation at an Academic Medical Center.
  Grego AR, Okuboyejo J, Escobar M, Academy of Managed Care Pharmacy Meeting (AMCP), 1/1/2018
• Efficacy of on-demand treatment of bleeding episodes in hemophilia B patients with extended half-life N9-GP in pivotal trials: an in-depth analysis of treatment.
  Escobar M, Walsh C, Cooper D, Young G, National Hemophilia Foundation Meeting, 1/1/2018
• Efficacy of an Extended Half-Life GlycoPEGylated rFVIII (N8-GP): Pooled Analysis of ABR (Results from 2 Clinical Trials).
  P Chowdary, L Poulsen, M Escobar, S Kearney, et al., American Society of Hematology Annual meeting, San Diego, CA, 1/1/2018
• Chronic Kidney Disease in the U.S. Hemophilia Population: A Cohort Study.
  Sood SL, Cheng D, Shapiro AD, Kessler CM,Key NS, Quon DV, Eyster E, Manco-Johnson MJ, Kempton CL,Cuker A, Ragni MV, Gill JC, Kuriakose P, Drygalski A, Kouides PA, Esco..., American Society of Hematology Annual meeting, San Diego, CA, 1/1/2018
• Low dose 4-factor Prothrombin Complex Concentrate in reversal of Xa Inhibitors in a Neuro ICU.
  AllisonT, Hartman H, Gass J, Lin PJ, Chong K, Choi HA and Escobar M', Society of Critical Care Medicine annual Congress� Texas Chapter. Winner of the Alan I. Fields Award; Critical Care Congress, Honolulu, HI, 2016, 1/1/2017
• Prophylaxis with rIX-FP reduces consumption compared with previous FIX in both adult and pediatric patients.
  M Escobar, E Santagostino, C Leissinger, A Shapiro, J Oldenburg, B Pan-Petesch, Wilfried Seifert, the PROLONG-9FP Investigators, XXVI Congress of the International Society of Thrombosis and Haemostasis; Res Prac Thromb Haemost, Berlin, Germany, 1/1/2017
• Prediction of outcome in acquired hemophilia A.
  Escobar M, Donnachie E, XXVI Congress of the International Society of Thrombosis and Haemostasis, Berlin, Germany, 1/1/2017
• Characterization of the HLA-class-II (HLAcII)/Therapeutic Factor VIII (FVIII)-Derived Peptidome by FVIII Domain and HLAcII Isomer.
  Almeida M, Diego VP, Luu BW, Hofmann M, Garcia-Hern�ndez A, Peralta J, Curran J, Escobar M, et al., XXVI Congress of the International Society of Thrombosis and Haemostasis, Berlin, Germany, 1/1/2017
• Consumption of rVIII-SingleChain during prophylaxis in adult, adolescent and pediatric patients.
  Pabinger i, Fischer K, Gill J, Santagostino E, Boggio L, Escobar M and Mahlangu J, XXVI Congress of the International Society of Thrombosis and Haemostasis, Berlin, Germany, 1/1/2017
• Once-weekly prophylaxis with GlycoPEGylated recombinant factor VIII (N8-GP) in severe haemophilia A: safety and efficacy results from a randomized phase 3 trial (pathf...
  Curry N, Albayrak C, Escobar M, Holme PA, Kearnev S, et al., XXVI Congress of the International Society of Thrombosis and Haemostasis, Berlin, Germany, 1/1/2017
• A phase 1/2a, open-label, multicenter, dose escalation study to assess the safety, pharmacokinetics and pharmacodynamics profile of a long-acting recombinant factor VI...
  Young G, Quon DV, Escobar MA, Boggio LN, et al., XXV-I Congress of the International Society of Thrombosis and Haemostasis, Berlin, Germany, 1/1/2017
• La profilaxis con rIX-FP reduce el consumo en comparaci�n con el concentrado de FIX anterior en pacientes adultos y pedi�tricos.
  Spanish Hemophilia Society Meeting, 1/1/2017
• Characterization of the HLA-class-II (HLAcII)/Therapeutic Factor VIII (FVIII)-Derived Peptidome by FVIII Domain and HLAcII Isomer.
  Almeida M, Diego VP, Luu BW, Hofmann M, Garcia-Hern�ndez A, Peralta J, Curran J, Escobar M, et al., American Society of Hematology Annual meeting, Atlanta, GA, 1/1/2017
• Prophylactic Efficacy of nonacog beta pegol once weekly in adult and pediatric patients with hemophilia B: a pooled analysis.
  Escobar M, Young G, Oldenburg J, Mahlangu J, et al., Thrombosis and Hemostasis Summit of North America (THSNA) Meeting, Chicago, IL, 1/1/2016
• Genetic variant analysis in children and adults with hemophilia: experience from a large hemophilia center in the US.
  Lemons J, Brown D, Cantini M, Cannon K, Rodriguez N, Nguyen T, and Escobar M, XXXII International Congress of the World Federation of Hemophilia, Orlando, FL, 1/1/2016
• Collecting clinical data through a care management assessment form during telephone patient encounters: A study among patients of the Gulf States Hemophilia and Thromb...
  Gustafson S, Lee M, Gonzaga C, and Escobar MA, XXXII International Congress of the World Federation of Hemophilia, Orlando, FL, 1/1/2016
• Anti-FVIII IgG1 titers correlate with Bethesda levels in patients with acquired hemophilia.
  Escobar MA, Smith KC, Donnachie E, XXXII International Congress of the World Federation of Hemophilia, Orlando, FL, 1/1/2016
• Peri-operative haemostatic management of major orthopaedic surgery in haemophilia B with long-acting recombinant glycoPEGylated factor IX: results from the paradigm�3 ...
  Escobar M, Colberg T, Karim F, Caliskan U, et al., XIV International Musculoskeletal Congress WFH, Belfast, Ireland, 1/1/2015
• Join now to see all

Lectures

• Consistency of Dosing of Turoctocog Alfa Pegol (N8-GP) throughout the Pathfinder Clinical Trials: Implications for Recommendations for Effective Prophylaxis, Bleed Res... 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Efficacy of an Extended Half-Life GlycoPEGylated rFVIII (N8-GP): Pooled Analysis of ABR (Results from Two Clinical Trials) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• New Therapeutic Options in Hemophilia 
  Mexico City, MX - 1/1/2018
• New Treatments in Hemophilia, including gene therapy 
  Nuevo Vallarta, Mexico - 1/1/2018
• How can we Decrease the Risk of inhibitors in Hemophilia 
  Nuevo Vallarta, Mexico - 1/1/2018
• �New Treatment Strategies for Hemophilia Management� 
  Republica Dominicana - 1/1/2017
• �Standard of Care for Hemophilia in the Developed World�. 
  Republica Dominicana - 1/1/2017
• �New Treatment Strategies for the Treatment of Bleeding Disorders� 
  University of Texas Health Science Center at Houston - 1/1/2017
• �DIC, Bleeding Disorders and Coagulopathy�. 
  Houston, TX - 1/1/2015
• �One in a Million: Rare Bleeding Disorders� 
  Dallas, TX - 1/1/2015
• �Rare Bleeding Disorders� 
  Dallas, TX - 1/1/2015
• �Management of Comorbidities in Hemophilia and vonWillebrand Disease� 
  Sao Paulo, Brazil - 1/1/2015
• �New Methods to Predict the Immunogenicity of Therapeutic Coagulation Proteins�. 
  Bethesda, MD - 1/1/2015
• �Management of other comorbidities in hemophilia� 
  Caracas, Venezuela - 1/1/2015
• �Prophylaxis in hemophilia. New therapeutic options.� 
  Chicago, IL - 1/1/2015
• �Treatment Options for prophylaxis in hemophilia�. 
  Texas Children's Hospital, Houston, TX - 1/1/2015
• �Hemophilia Care in Developed Countries�. 
  Panama City, Panama - 1/1/2014
• �Ask the Experts: inhibitors in Hemophilia� 
  Washington, DC - 1/1/2014
• �Update on Coagulation Assays. More Than Just PT/PTT� 
  Cali, Colombia - 1/1/2014
• �Emerging Coagulation Factors for Hemophilia� 
  Cali, Colombia - 1/1/2014
• �Appropriate Use of Blood Components in a Modern Acute Care Hospital� 
  Houston, TX - 1/1/2014
• �Blood Utilization Program� 
  Memorial Hermann Hospital, TMC - 1/1/2014
• �Prophylaxis in Hemophilia�. 
  Mexico City - 1/1/2013
• �Management of Patients with inhibitors� 
  1/1/2013
• �The Obesity Epidemic: Weight Management, Bariatric Surgery & Related Cosmetic Surgery” 
  Anaheim, CA - 1/1/2013
• Join now to see all